The TrialNet low-dose ATG/G-CSF clinical trial in individuals with recent-onset T1D was a multisite, 3-arm, randomized, placebo-controlled, double-blind study that enrolled 89 pediatric and adult participants, 12–45 years old, as previously described (9) and reviewed in Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.161812DS1 Eighty-eight participants underwent detailed mechanistic analysis. The gene discussed is CSF3; the disease is type 1 diabetes mellitus.